Adipogen/LEE011/SYN-1213-M001/1 mg
商品编号：
SYN-1213-M001
品牌：
Adipogen Inc
市场价：
¥1080.00
美元价：
648.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | LEE-011; Ribociclib |
| Product Type | Chemical |
| Properties | |
| Formula | C23H30N8O |
| MW | 434.5 |
| CAS | 1211441-98-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: CDK4/CDK6 | Kinase Group: CGMC | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | RHXHGRAEPCAFML-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Product References
- Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma: J. Rader, et al.; Clin. Cancer Res. 19, 6173 (2013)
- Molecular pathways: CDK4 inhibitors for cancer therapy: M.A. Dickson; Clin. Cancer Res. 20, 3379 (2014)
- Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo: Y.X. Zhang, et al.; Mol. Cancer Ther. 13, 2184 (2014)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
